Genetic variants in UBQLN1 gene have been linked to neurodegeneration and mutations in UBQLN2 have recently been identified as a rare cause of amyotrophic lateral sclerosis (ALS). Objective: To test if genetic variants in UBQLN1 are involved in ALS. Methods: 102 and 94 unrelated patients with familial and sporadic forms of ALS were screened for UBQLN1 gene mutations. Single nucleotide variants were further screened in a larger set of sporadic ALS (SALS) patients and unrelated control subjects using high-throughput Taqman genotyping; variants were further assessed for novelty using the 1000Genomes and NHLBI databases. In vitro studies tested the effect of UBQLN1 variants on the ubiquitin-proteasome system (UPS). Results: Only two UBQLN1 coding variants were detected in the familial and sporadic ALS DNA set; one, the missense mutation p.E54D, was identified in a single patient with atypical motor neuron disease consistent with Brown-Vialetto-Van Laere syndrome (BVVLS), for whom c20orf54 mutations had been excluded. Functional studies revealed that UBQLN1 E54D protein forms cytosolic aggregates that contain mislocalized TDP-43 and impairs degradation of ubiquitinated proteins through the proteasome. Conclusions: Genetic variants in UBQLN1 are not commonly associated with ALS. A novel UBQLN1 mutation (E45D) detected in a patient with BVVLS altered nuclear TDP-43 localization in vitro, suggesting that UPS dysfunction may also underlie the pathogenesis of this condition.
Introduction
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset degenerative motor neuron disease (MND). The incidence of ALS is 1-2 per 100,000, the prevalence is 4-6 per 100,000 and the lifetime ALS risk is approximately 1/600 (McGuire et al., 1996; Mitsumoto et al., 1998) . While most ALS cases are sporadic (SALS), approximately 10% are familial (FALS). The most common genetic cause in FALS is the recently defined expansion of a hexanucleotide repeat in the non-coding region of C9orf72 and mutations in the gene encoding cytosolic superoxide dismutase 1 (SOD1), which together may account for at least 50% of FALS cases (Dejesús-Hernández et al., 2011; Renton et al., 2011; Rosen et al., 1993) . Mutations in TAR DNA binding protein (TARDBP) and fused-in-sarcoma/translated-in-liposarcoma (FUS/TLS) genes each account for about 5% of FALS cases (Kabashi et al., 2008; Kwiatkowski et al., 2009; Sreedharan et al., 2008; Vance et al., 2009) . Less frequently, mutations in genes encoding vesicle-associated membrane proteinassociated protein B (VAPB), senataxin (SETX), dynactin (DCTN1), alsin (ALS2), angionenin (ANG), optineurin (OPTN), valosin-containing protein (VCP) are predicted to cause FALS (Chen et al., 2004; Greenway et al., 2006; Johnson et al., 2010a; Maruyama et al., 2010; Münch et al., 2005; Nishimura et al., 2004; Yang et al., 2001) . Recently, some cases of X-linked ALS have been ascribed to mutations in UBQLN2 (Deng et al., 2011) .
Genetic variants in ubiquilin 1 (UBQLN1) have been linked to neurodegeneration. Two family-based cohorts showed a positive association Available online on ScienceDirect (www.sciencedirect.com). 1 These authors contributed equally to this work.
